Beneficial effect by Xanthine oxidase inhibitor on endothelial function beyond Uric Acid trial
Latest Information Update: 16 Oct 2024
At a glance
- Drugs Topiroxostat (Primary) ; Febuxostat
- Indications Hyperuricaemia
- Focus Therapeutic Use
- Acronyms BEYOND-UA-trial
- 05 Jan 2021 Primary endpoint has not been met. (Changes in CAVI from baseline to 24 weeks), according to results published in the Journal of Clinical Hypertension (Greenwich).
- 05 Jan 2021 Status changed from active, no longer recruiting to completed, according to Results published in the Journal of Clinical Hypertension (Greenwich).
- 05 Jan 2021 Results published in the Journal of Clinical Hypertension (Greenwich)